Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma": [Ann Oncol 35 (2024) 1039-1047].

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry.

British journal of haematology·2024
Same author

Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study.

Annals of hematology·2023
Same author

Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA.

British journal of haematology·2023
Same author

Management of patients with multiple myeloma in the era of COVID-19 pandemic: how hospital at home changes our medical practice.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2021
Same journal

[Abdominal pain, fever and arthralgia in a 49-year-old woman].

La Revue de medecine interne·2026
Same journal

[Cardiorespiratory functional disorders: A transnosologic approach].

La Revue de medecine interne·2026
Same journal

[Diagnostic evaluation for suspected polycythemia].

La Revue de medecine interne·2026
Same journal

Heart involvements in systemic sclerosis beyond pulmonary hypertension: From conduction, rhythm and function defects to coronary artery disease.

La Revue de medecine interne·2026
Same journal

[Acute intermittent porphyria: When diagnostic errance jeopardizes patient health].

La Revue de medecine interne·2026
Same journal

Autosomal dominant polycystic kidney disease: Current perspectives in 2026.

La Revue de medecine interne·2026
See all related articles

Related Experiment Video

Updated: May 7, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

[Smoldering multiple myeloma].

G Fouquet1, S Guidez1, C Herbaux1

  • 1Service des maladies du sang, hôpital Huriez, CHRU de Lille, rue M.-Polonovski, 59037 Lille, France.

La Revue De Medecine Interne
|September 21, 2013
PubMed
Summary
This summary is machine-generated.

Smoldering multiple myeloma (SMM) is a precursor to multiple myeloma. Identifying high-risk SMM patients for early treatment is crucial to prevent progression and complications, though current recommendations favor observation.

Keywords:
Gammapathie monoclonale de signification indéterminéeMonoclonal gammapathy of undetermined significanceMultiple myelomaMyélomeMyélome multiple indolentSmoldering multiple myeloma

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Related Experiment Videos

Last Updated: May 7, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Area of Science:

  • Hematology
  • Oncology
  • Clinical Medicine

Context:

  • Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder.
  • SMM has a significant risk of progressing to active multiple myeloma.
  • Distinguishing SMM from monoclonal gammopathy of undetermined significance (MGUS) and active multiple myeloma is critical.

Purpose:

  • To explore the potential benefits of early therapeutic intervention in high-risk SMM patients.
  • To address the challenge of identifying SMM patients who would benefit from early treatment versus those who would not.
  • To evaluate if early treatment can delay progression and reduce complications.

Summary:

  • SMM is characterized by monoclonal plasma cell proliferation without end-organ damage, but with a high risk of progression.
  • The key management question is whether early treatment can delay progression to multiple myeloma and its complications.
  • Identifying high-risk SMM patients for intervention is challenging due to the asymptomatic nature and potential treatment toxicity.

Impact:

  • Early identification of high-risk SMM could lead to timely intervention, potentially altering disease course.
  • This research aims to inform clinical decision-making regarding SMM management strategies.
  • Optimizing SMM treatment could improve patient outcomes and reduce the burden of multiple myeloma.